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The Centers for Disease Control and Prevention 
(CDC) strives to prevent viral hepatitis infections 
and to eliminate disease and mortality caused 
by viral hepatitis. CDC prioritizes public health 
actions needed to achieve four strategic 
objectives:
1. Ensure vulnerable populations are 
vaccinated against viral hepatitis;
2. Ensure early detection and response to stop 
transmission of hepatitis B and hepatitis C;
3. Ensure persons living with hepatitis B 
and hepatitis C are diagnosed, linked to 
recommended care, and treated; and
4. Act globally to prevent, detect, and control 
viral hepatitis transmission, illness, and 
associated mortality in the United States.
This inaugural report on viral hepatitis elimination 
in the United States provides information on 
progress in the implementation of recommended 
interventions and the impact these interventions 
are having on prevention of viral hepatitis 
transmission, disease, and associated mortality. 
Data contained in this report are used to monitor 
health outcomes (e.g., new infections and 
mortality) and to track the status of preventive 
interventions (e.g., vaccination) that can improve 
these health outcomes. Data are presented by 
age, sex, race/ethnicity, and other variables to 
evaluate disparities between segments of the 
U.S. population; such evaluation can be used to 
guide implementation of effective interventions. 
In this report, progress toward achieving selected 
2020 goals is evaluated against annual targets 
for program performance and improvements 
in health outcomes. The 2020 goals compiled 
Hepatitis A vaccination coverage 
has increased, contributing 
to declines in HAV infections 
among young children and 
adolescents. The variability in hepatitis 
A incidence rates among adults over time 
highlights the importance of public health 
surveillance to identify and respond to 
outbreaks of hepatitis A. 
Over a quarter of all newborns 
do not receive hepatitis B 
vaccination within 3 days of 
birth, leaving children unnecessarily 
vulnerable to HBV infection and disease. 
The opioid epidemic (and injection 
of other substances) is largely 
responsible for increases in the 
incidence rates of hepatitis B 
and hepatitis C. The trends reflect 
inadequate access to effective prevention 
strategies, including syringe services 
programs, hepatitis B vaccination, and 
testing and treatment for persons infected 
with HBV or HCV. 
After decades of annual 
increases in HCV-related 
mortality, death rates declined 
slightly in 2015. Despite this change, 
the number of deaths related to HCV 
continues to exceed deaths from all other 














specifically for this report were adapted from 
other initiatives such as Healthy People 2020 
when available; however, no single, existing 
initiative comprehensively or consistently 
evaluates all indicators considered critical for 
monitoring the burden of viral hepatitis in the 
nation. The 2014 
baseline year 











targets assume a linear rate of change from the 
observed 2014 baseline to the 2020 goal. CDC 
intends to update this report annually to reflect 
changes in performance measures, indicators of 
health outcomes, and available data sources.
This National Progress Report includes current 
epidemiologic information and key findings for 
the prevention of hepatitis A virus (HAV), hepatitis 
B virus (HBV), and hepatitis C virus (HCV) 
infections, as these infections are responsible 
for most illnesses and deaths caused by viral 
hepatitis in the United States. The following text 
summarizes this information for each type of viral 
hepatitis infection. 
Results available as of May 1, 2017 show areas 
where the nation is making good progress 
and areas where the nation can improve.
Hepatitis A: The rate of reported new HAV infections 
rose from 0.39 per 100,000 U.S. population in 2014 to 
0.43 per 100,000 in 2015. The percentage of children aged 
19–35 months receiving ≥2 doses of hepatitis A vaccine 
was 58% in 2014 and 60% in 2015, lower than both the 
2015 target (62%) and the 2020 goal (85%). Hepatitis A 
vaccination coverage among children aged 19-35 months 
may have contributed to a drop in hepatitis A incidence 
rates to levels below the 2020 goal of 0.3 per 100,000 
U.S. population among persons 0-19 years. In contrast, 
the incidence of hepatitis A for all other age groups rose 
slightly in 2015, moving away from the 2020 goal of 0.3 cases per 100,000 
U.S. population. The annual variability in HAV incidence rates reflects, in part, outbreaks among 
unvaccinated adults attributed to consumption of HAV-contaminated imported food, or person-
to-person contact in certain settings. Hepatitis A vaccination is recommended for children 
beginning at one year of age and for persons who inject drugs, men who have sex with men, 
travelers to hepatitis A endemic countries, persons with chronic liver disease, and other adults 













Hepatitis B: The 2020 goal (0.48 per 100,000 U.S. 
population) for a reduction in HBV-related deaths was 
exceeded in 2015 (0.45 per 100,000). The ongoing 
challenges of HBV as a public health threat include 
low hepatitis B vaccination coverage among high-risk 
populations and an increase in the rate of new HBV 
infections. In 2005, CDC recommended all infants receive 
a birth dose of hepatitis B vaccine. Since that time, the 
percentage of newborns receiving hepatitis B vaccine 
within 3 days of birth increased to a high of 74% in 2013; 
coverage was 72% in 2014 and 2015, below the 2020 
goal of 85%. Equally concerning is the increase in rates 
of new HBV infections among adults, particularly those 
30-59 years of age. The persistent low coverage of 
hepatitis B vaccination among high-risk adults, increases 
in injection drug use related to the nation’s opioid crisis, 
and increases in other risk behaviors contributed to this increase.  
Hepatitis C: After decades of annual increases, the rate of HCV-related deaths decreased from 
5.01 per 100,000 U.S. population in 2014 to 4.91 per 100,000 in 2015, but did not reach the 
2015 target (4.87 per 100,000). The rate of reported new 
acute HCV infections increased from 0.74 per 100,000 
U.S. population in 2014 to 0.81 per 100,000 in 2015, well 
above the 2020 goal (0.25 per 100,000). Young adults aged 
20-39 years had the highest reported incidence rate of 
acute HCV infection in 2015, and rates for this age group 
are increasing faster than for other adults. In 2015, HCV 
infection incidence rates were highest among American 
Indians/Alaskan Natives (1.76 per 100,000 U.S. population) 
and white persons (0.92 per 100,000). Increases in 
incidence rates were observed because of increased 
HCV testing and from actual increases in new infections 
associated with a rise in injection drug use related to the 




















Please refer to the Indicator Summaries 
and Technical Notes sections for 
additional information on each of the 
indicators listed below.










Increase the percentage of children aged 19–35 
months who receive ≥2 doses of hepatitis A vaccine 
85.0% 62.1% 57.5% 59.6%
Reduce the rate2 of reported HAV infections 0.30 0.38 0.39 0.43
Hepatitis B
Increase the percentage of infants who receive 
hepatitis B vaccine within 3 days of birth 
85.0% 74.5% 72.4% 72.4%
Reduce the rate2 of reported acute HBV 
infections among persons aged ≥19 years
0.50 1.05 1.16 1.38
Reduce the rate2 of HBV-related deaths 0.48 0.50 0.50 0.45
Hepatitis C
Reduce the rate1 of reported acute HCV 
infections
0.25 0.66 0.74 0.81
Reduce the rate2 of HCV-related deaths 4.17 4.87 5.01 4.91
1Target for 2015 assumes a constant (linear) rate of change from the observed baseline (2014) to the 2020 goal
2Per 100,000 U.S. population
Met or exceeded current annual target
Not met—moved toward annual target in most recent 
data year
Not met—no change or moved away from annual target 
in most recent data year
Annual targets and 
results represent the 
most current available 
data. See Indicator 
Summaries and 














Viral hepatitis, particularly hepatitis B virus (HBV) 
and hepatitis C virus (HCV), is a major cause of 
disease and mortality in the United States and 
worldwide. Globally, 257 million and 71 million 
persons are estimated to be living with chronic 
HBV and HCV infection, respectively.1 In 2013, 
viral hepatitis took approximately 1.4 million 
lives, a global death toll surpassing those of road 
injuries, diabetes, and malaria.2 In the United 
States, as many as 4.4 million persons are living 
with HBV or HCV infection, which together are 
major causes of chronic liver disease and liver 
cancer.3-4 In contrast to the declining rate of 
deaths from other cancers, deaths from liver 
cancer are rising in the United States, with much 
of the increase attributed to viral hepatitis.5 Of 
particular concern is the annual number of HCV-
related deaths, which now exceeds the number 
of deaths from the 60 other nationally notifiable 
diseases combined.6
New cases of viral hepatitis are on the rise in the 
United States. The rate of new HCV infections 
reported to the Centers for Disease Control and 
Prevention (CDC) increased by 167% nationally 
from 2010 to 2015, with most new infections 
occurring among adolescents and young adults. In 
2015, the rate of new HBV infections rose because 
of increased transmission among persons who 
inject drugs (PWID) and those with other HBV-
related risks.7 This upward trend in incidence rates 
is not inevitable. New cases of viral hepatitis can 
be prevented with effective interventions. For 
instance, effective vaccines can protect persons 
from becoming infected with HAV and HBV. Other 
preventive measures include screening of tissue/
organ donations, stringent infection control in 
healthcare settings, safer sexual practices, and 
access to clean injection equipment for PWID.
Testing, care, and treatment greatly reduce 
mortality risks while improving quality of life for 
persons living with HBV and HCV infection. In 
the United States, fewer than half of persons 
living with hepatitis C know they are infected.8 
Only through testing and knowledge of infection 
status can persons with hepatitis B or C receive 
the care and treatment that can vastly improve 
their health outcomes. Therapy for HBV reduces 
mortality risks from liver cancer, and licensed 
HCV therapies are capable of curing more than 
90% of HCV-infected persons who complete 
treatment.9 Persons who achieve virologic cure 
of their HCV infection have dramatically lower 
risks of liver cancer and other life-threatening 
conditions and experience higher quality of life 
(e.g., less fatigue and fewer mental health issues) 
than those who remain infected.
Certain U.S. populations are disproportionately 
affected by and die from hepatitis B (e.g., Asians/
Pacific Islanders, persons aged 55–64 years, 
and persons infected at birth) and hepatitis C 












Americans, and American Indians/Alaskan 
Natives). These populations need increased, 
targeted interventions that can prevent 
new cases of infection (e.g., education and 
vaccination). For persons in these populations 
who are living with chronic viral hepatitis, better 
access to hepatitis care and treatment is needed, 
as linking infected persons to these services 
improves quality of life.
National efforts to prevent new hepatitis A, 
hepatitis B, and hepatitis C infections and 
associated morbidity and mortality are taking 
place at multiple levels. Guided by four strategic 
imperatives (i.e., ensure vulnerable populations 
are vaccinated, stop transmission, identify and 
link infected persons to recommended care and 
treatment services, and detect and control viral 
hepatitis globally) outlined within CDC’s Viral 
Hepatitis Strategic Plan, 2016-2020, CDC has 
selected specific prevention activities based 
on a high-impact prevention approach. The 
most cost-effective, scalable interventions are 
aligned with the populations and geographic 
areas with the highest burden of viral hepatitis, 
maximizing the impact of federal prevention 
dollars and advancing collective progress toward 
achieving health gains for the nation. Developed 
by the U.S. Department of Health and Human 
Services (HHS), HHS’s National Viral Hepatitis 
Action Plan, 2017-2020 outlines the prevention 

















The title of this National Progress Report, 
Progress Toward Viral Hepatitis Elimination in the 
United States, reflects the growing consensus 
that viral hepatitis, specifically hepatitis B  and 
hepatitis C, can be eliminated as a public health 
threat. With support from the 2016 World 
Health Assembly, the World Health Organization 
released a Global 
Health Sector 
Strategy on Viral 
Hepatitis 2016-
2021, which aims 
to eliminate viral 
hepatitis as a 
public health 
threat. The goals 
for this strategy 
are to implement 
the necessary 
interventions 
to reduce the 
number of new 
HBV and HCV 
infections by 90% and reduce viral hepatitis-
related mortality by 65% by 2030. Guided by 
this global strategy, in March 2017, the U.S. 
National Academies of Sciences, Engineering, 
and Medicine released A National Strategy for 
the Elimination of Hepatitis B and C, challenging 
the nation to implement actions necessary to 
eliminate hepatitis B and hepatitis C as public 
health threats in the United States by 2030. 
Measuring Progress
The seven indicators in this report provide 
an objective way to assess progress toward 
achieving key viral hepatitis goals. They 
provide feedback that guides CDC’s planning 
efforts and program improvement activities. 
The data for these indicators come from CDC’s 
National Immunization Survey-Child (NIS-Child), 
National Notifiable Diseases Surveillance 
System (NNDSS), and National Vital Statistics 
System (NVSS). Accurate and timely reporting 













The 2020 goals compiled specifically for this 
report were adapted from other initiatives such as 
Healthy People 2020 Objectives, HHS’s National 
Viral Hepatitis Action Plan, 2017-2020, and CDC’s 
Viral Hepatitis Strategic Plan, 2016-2020; however, 
no single, existing initiative comprehensively or 
consistently evaluates all indicators considered 
critical for monitoring the burden of viral hepatitis 
in the nation. The relationship of each indicator in 
this report to other initiatives is described in the 
Technical Notes.  
This report evaluates progress by comparing 
results with annual targets. Annual targets are 
based on the assumption that change will occur 
equally over time. For each indicator, a 2014 
baseline year was identified as the starting point 
for setting annual targets. 
No statistical tests are used to assess changes 
over time, differences between groups, or 
differences between the result and the annual 
target or 2020 goal. Statistically significant 
change is not an expectation for progress from 
one year to the next and may not always be 
necessary to achieve the 2020 goal. Additional 
data for some indicators are available in other 
publications and may include information about 
statistical significance.
Technical Notes provide additional information 
about the baseline, annual targets, and 2020 
goal selected for each indicator, as well as the 
data sources and estimation methods used for 
measuring those indicators. 
Symbols provide a visual confirmation of 
progress for each indicator (i.e., observed 2015 
data relative to annual targets); the following 
symbols are used in this report:
Met or exceeded current annual target
Not met—moved toward annual target in 
most recent data year
Not met—no change or moved away from 
annual target in most recent data year
CDC Viral Hepatitis 
Surveillance Systems:  
Data Sources for Indicators
National Immunization Survey-Child 
(NIS-Child): The NIS-Child is a dual 
sample frame telephone survey of parents 
of children aged 19-35 months with a 
follow-up mail survey of vaccination 
providers, and it is used to monitor 
vaccination coverage among young 
children. The NIS-Child is sponsored and 
conducted by CDC’s National Center for 
Immunization and Respiratory Diseases 
(NCIRD). 
National Notifiable Diseases 
Surveillance System (NNDSS): The 
NNDSS is a nationwide, collaborative 
surveillance system that enables all levels 
of public health to share notifiable-disease-
related health information. As part of 
NNDSS, health departments notify CDC 
about the occurrence of certain conditions. 
The Division of Health Informatics and 
Surveillance (DHIS) at CDC supports 
NNDSS by receiving, securing, processing, 
provisioning, and releasing nationally 
notifiable infectious disease data to 
disease-specific CDC programs, including 
the Division of Viral Hepatitis.
National Vital Statistics System (NVSS): 
Vital statistics data, including all births 
and deaths, are registered in each of 
the 50 states, the District of Columbia, 
New York City, and five territories (Puerto 
Rico, the Virgin Islands, Guam, American 
Samoa, and the Commonwealth of the 
Northern Mariana Islands). CDC’s National 
Center for Health Statistics (NCHS) in 
turn collects these data from each of the 
jurisdictions and compiles them into the 












Federal Monitoring and Reporting Activities
The indicators and goals in this report were adapted from other federal performance monitoring and 
reporting activities when available:
Healthy People 2020 — Healthy People 2020 Objectives are science-based national 
objectives for improving the health of all Americans and measuring the impact of 
prevention activities. Objectives related to viral hepatitis are described under the 
Immunization and Infectious Diseases Topic Area.
Department of Health and Human Services (HHS) — HHS’s National Viral Hepatitis 
Action Plan, 2017-2020 outlines priorities and collaborations needed to expand access 
to interventions, clinical care, and treatment.
Centers for Disease Control and Prevention (CDC) — CDC’s Viral Hepatitis Strategic 
Plan, 2016-2020 outlines strategic imperatives and specific goals to accomplish the 
agency’s high-impact prevention approach.
The relationship of each indicator in this report to other initiatives is described in the Technical Notes.
Summary of Results
Results available as of May 1, 2017, reveal 
national progress made toward reaching 
prevention goals. Data also highlight the viral 
hepatitis interventions that should be sustained 
and those that are in need of improvement. 
Of seven indicators with accompanying goals 
for improved health outcomes related to viral 
hepatitis transmission and disease, only one 
indicator met the 2020 goal in 2015 (reduce the 
rate of HBV-related deaths to 0.48 per 100,000 
U.S. population). For two indicators, annual 
targets were not met, but data appear to be 
trending toward reaching prevention goals. For 
four indicators, annual targets were not met, 
and either no change occurred or data appear to 
trend further from the goal. Progress indicators 
are organized according to each of the three 
viral hepatitis types: hepatitis A, hepatitis B, and 
hepatitis C. Within each type, indicators are listed 
in the following order: prevention of transmission 
(i.e., primary prevention, such as vaccination 
coverage), incidence, prevention of morbidity 
(i.e., secondary prevention), and finally, mortality.
Hepatitis A
The rate of reported new HAV infections rose 
from 0.39 per 100,000 U.S. population in 2014 
to 0.43 per 100,000 in 2015. The percentage of 
children aged 19–35 months receiving ≥2 doses 
of hepatitis A vaccine was 58% in 2014 and 60% 
in 2015, lower than both the 2015 target (62%) 
and the 2020 goal (85%). Hepatitis A vaccination 
coverage among children aged 19-35 months 
may have contributed to a drop in hepatitis A 
incidence rates to levels below the 2020 goal of 
0.3 per 100,000 U.S population among persons 
0-19 years. In contrast, the incidence of hepatitis 
A for all other age groups rose slightly in 2015, 
moving away from the 2020 goal of 0.3 cases 
per 100,000 U.S. 
population. The 
annual variability 
in HAV incidence 

















imported food or person-to-person contact 
in certain settings. Hepatitis A vaccination is 
recommended for children beginning at one year 
of age and for persons who inject drugs, men 
who have sex with men, travelers to hepatitis 
A endemic countries, persons with chronic liver 




goal (0.48 per 
100,000 U.S. 
population) for 







challenges of HBV as a public health threat 
include low hepatitis B vaccination coverage 
among high-risk populations and an increase in 
the rate of new HBV infections. In 2005, CDC 
recommended all infants receive a birth dose 
of hepatitis B vaccine. Since that time, the 
percentage of newborns receiving hepatitis B 
vaccine within 3 days of birth increased to a 
high of 74% in 2013; coverage was 72% in 2014 
and 2015, below the 2020 goal of 85%. Equally 
concerning is the increase in rates of new HBV 
infections among adults, particularly those 30-59 
years of age. The persistent low coverage of 
hepatitis B vaccination among high-risk adults, 
increases in injection drug use related to the 
nation’s opioid crisis, and increases in other risk 
behaviors contributed to this increase.
Hepatitis C
After decades of annual increases, the rate of 
HCV-related deaths decreased from 5.01 per 
100,000 U.S. population in 2014 to 4.91 per 
100,000 in 2015, but did not reach the 2015 
target (4.87 per 100,000). The rate of reported 
new acute HCV infections increased from 0.74 
per 100,000 U.S. population in 2014 to 0.81 per 
100,000 in 2015, well above the 2020 goal (0.25 
per 100,000). Young adults aged 20-39 years had 
the highest reported incidence rate of acute HCV 
infection in 2015, and rates for this age group 
are increasing faster than for other adults. In 
2015, HCV infection incidence rates were highest 
among American Indians/Alaskan Natives (1.76 
per 100,000 U.S. population) and white persons 
(0.92 per 100,000). Increases in incidence rates 
were observed because of increased HCV testing 
and from actual increases in new infections 
associated with a rise in injection drug use 
related to the opioid use epidemic.
Looking Forward
To allow routine 
monitoring of progress 
and timely identification 
of areas in need of 
improvement, CDC’s Viral 
Hepatitis Program intends 
to update this report 
annually. Future National 
Progress Reports will be 
modified as needed to 
reflect any changes in 
indicators, available data 
sources, and types of 
outcome measures. 
Future NPRs will focus on the following updated indicators:
Increase the percentage of children aged 19–35 months  
who receive ≥2 doses of hepatitis A vaccine
Reduce the rate of reported HAV infections
Increase the percentage of infants who receive  
hepatitis B vaccine within 3 days of birth
Reduce the rate of reported acute HBV infections  
among persons aged ≥19 years
Reduce the rate of HBV-related deaths
Reduce the rate of reported acute HCV infections
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Hepatitis   A
Increase the percentage of children aged 19–35 months  
who receive ≥2 doses of hepatitis A vaccine .  .  .  .  .  .  .  .  .  .  14
























A Increase the percentage of children aged 19–35 months who receive ≥2 doses of 
hepatitis A vaccine
Percentage of children aged 19–35 months* 
who received ≥2 doses of hepatitis A vaccine
STATUS
Source: CDC, National Immunization Survey-Child10-11 
*For 2010, children born 1/2007-5/2009; for 2011, children born 1/2008-5/2010; for 2012, children born 1/2009-5/2011; for 2013, children born 
1/2010-5/2012; for 2014, children born 1/2011-5/2013; and for 2015, children born 1/2012-5/2014.
The percentage of children 
aged 19–35 months receiving 
≥2 doses of hepatitis A vaccine 
has increased since 2010, 
reaching 59.6% in 2015; despite 
this increase, the 2015 target 
of 62.1% was not met. Although 
single-dose vaccination rates 
are relatively high among 
children, multiple doses are 
needed for full coverage, 
and most adults were not 
vaccinated against hepatitis A 
virus as children, leaving many 
susceptible to infection. 
Increase needed to 
meet 2020 goal: 
A 42.6% increase over the vaccination 
percentage reported in 2015 is needed to 
meet the 2020 goal of 85%.
This increase can best be achieved by 
• Identifying and removing barriers to hepatitis A vaccination among 
children by implementing evidence-based strategies recommended 
by the Community Preventive Services Task Force to increase 
vaccination.
• Ensuring that providers continue to follow existing immunization 
schedules and Advisory Committee on Immunization Practices (ACIP) 
Vaccine Recommendations and Guidelines.
























Percentage of children aged 19-35 months in 2015* 
who received ≥2 doses of hepatitis A vaccine, by
race/ethnicity†
In 2015, non-Hispanic Asian 
children aged 19-35 months 
had the highest percentage 
receiving ≥2 doses of 
hepatitis A vaccine (67.8%). 
Multiple race children had 
the lowest percentage 
(54.1%).
Percentage of children aged 19-35 months in 2015* 
who received ≥2 doses of hepatitis A vaccine, by
poverty level‡
In 2015, a lower percentage of 
children aged 19-35 months in 
households with a total family 
income less than the poverty 
threshold received ≥2 doses of 
hepatitis A vaccine compared 
with those in households at or 
above the poverty level (56.0% 
vs. 61.7%, respectively). 
Source: CDC, National Immunization Survey-Child10
*Children born 1/2012-5/2014.
†Race/ethnicity was reported by parent/guardian respondent. Children of Hispanic ethnicity may be of any race. Children identified as multiple 
race had more than one race category selected. Children identified as white, black, Asian, Native Hawaiian/other Pacific Islander, American 
Indian/Alaska Native, or multiple races were non-Hispanic. 
‡Children were classified as below poverty if their total family income was less than the poverty threshold specified for the applicable family size 
and number of children aged <18 years. Children with total family income at or above the poverty threshold specified for the applicable family 
size and number of children aged <18 years were classified as at or above poverty. Four hundred ninety two children with adequate provider data 
























A Reduce the rate of reported HAV infections 
Incidence rate* of reported HAV infections
STATUS
Source: CDC, National Notifiable Diseases Surveillance System (data run, April 28, 2017)
*Rate per 100,000 U.S. population
Although the incidence rate of 
reported HAV infections has 
declined over time, it increased 
from 2014 through 2015. With 
a 2015 annual incidence rate 
of 0.43 cases per 100,000 U.S. 
population, the 2015 target of 
0.38 per 100,000 was not met. 
The incidence rate of HAV is 
subject to variation, in large 
part due to HAV outbreaks. 
For example, in 2013, a large 
HAV outbreak occurred among 
persons who consumed 
imported pomegranate seeds 
in several southwestern states 
and Hawaii. 
Reduction needed 
to meet 2020 goal: 
A 30.2% reduction from the incidence rate 
reported in 2015 is needed to meet the 2020 
goal of 0.30 cases per 100,000 U.S. population. 
This reduction can best be achieved by 
• Updating CDC recommendations for hepatitis A vaccination (including 
post-exposure prophylaxis) to target vaccination among emerging 
at-risk populations.
• Assisting state and local health departments and other federal 
partners in outbreak detection and response.
• Promoting evidence-based strategies recommended by the 
Community Preventive Services Task Force to increase vaccinations.
• Analyzing surveillance data and other strategic information to detect 
populations at risk and gaps in vaccination coverage.
• Continuing to promote routine childhood vaccination schedules and 
























Incidence rate* of reported HAV infections, by sex
Men and women have 
similar incidence rates 
of HAV; men have slightly 
higher rates in the most 
recent years.
Incidence rate* of reported HAV infections, by age group
Young adults aged 20-29 
years have the highest 
incidence rates of HAV. 
Children 0-19 years of age 
have the lowest incidence 
rates of HAV, having 
achieved the 2020 goal of 
0.30 cases per 100,000 U.S. 
population. 
Incidence rate* of reported HAV infections, by race/ethnicity
Asian/Pacific Islanders 
have the highest incidence 
rates of HAV. Non-Hispanic 
black and American Indian/
Alaska Native persons 
have the lowest incidence 
rates of HAV, both groups 
having already met the 
2020 goal of 0.30 cases per 
100,000 U.S. population.
Source: CDC, National Notifiable Diseases Surveillance System7 
*Rate per 100,000 U.S. population
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Increase the percentage of infants who 
receive hepatitis B vaccine within 3 days  
of birth
Percentage of children aged 19-35 months* who 
received hepatitis B vaccine within 3 days of birth†
STATUS
Source: CDC, National Immunization Survey-Child10-11
*For 2010, children born 1/2007-5/2009; for 2011, children born 1/2008-5/2010; for 2012, children born 1/2009-5/2011; for 2013, children born 
1/2010-5/2012; for 2014, children born 1/2011-5/2013; and for 2015, children born 1/2012-5/2014.
†One dose of hepatitis B vaccination administered from birth through age 3 days.
The percentage of infants 
receiving hepatitis B vaccine 
within 3 days of birth increased 
from 64.1% in 2010 to 74.2% in 
2013 and was 72.4% in 2014 and 
2015, below the 2015 annual 
target of 74.5% coverage. 
Increase needed to 
meet 2020 goal: 
A 17.4% increase from the vaccination 
percentage reported in 2015 is needed to meet 
the 2020 goal of 85%. 
This increase can best be achieved by 
• Ensuring that providers continue to follow existing immunization 
schedules and Advisory Committee on Immunization Practices (ACIP) 
Vaccine Recommendations and Guidelines.
• Assisting birthing facilities in implementing routine vaccination of all 
newborns before hospital discharge.
• Assessing hospital measures and reimbursement policies to identify 
and remove any barriers to infants receiving the birth dose.
• Promoting the existing National Quality Forum (NQF)-Endorsed® 
























Percentage of children aged 19-35 months in 2015* who 
received hepatitis B vaccine within 3 days of birth†, by race/ethnicity
‡
In 2015, American Indian/
Alaska Native children had 
the highest percentage 
receiving hepatitis B 
vaccine within 3 days of 
birth (80.7%). Non-Hispanic 
white children had the 
lowest percentage (68.2%).
Percentage of children aged 19-35 months in 2015* who 
received hepatitis B vaccine within 3 days of birth†, by poverty level
¶
In 2015, a lower percentage of 
children in households with a 
total family income at or above 
the poverty threshold received 
hepatitis B vaccine within 3 
days of birth compared with 
those in households below the 
poverty level (70.2% vs. 76.3%, 
respectively). 
Source: CDC, National Immunization Survey-Child10
*Children born 1/2012-5/2014.
†One dose of hepatitis B vaccination administered from birth through age 3 days.
‡Race/ethnicity was reported by parent/guardian respondent. Children of Hispanic ethnicity may be of any race. Children identified as multiple 
race had more than one race category selected. Children identified as white, black, Asian, Native Hawaiian/other Pacific Islander, American 
Indian/Alaska Native or multiple races were non-Hispanic.
¶Children were classified as below poverty if their total family income was less than the poverty threshold specified for the applicable family size 
and number of children aged <18 years. Children with total family income at or above the poverty threshold specified for the applicable family 
size and number of children aged <18 years were classified as at or above poverty. Four hundred ninety two children with adequate provider data 
























B Reduce the rate of reported acute HBV infections among persons aged ≥19 years
Incidence rate* of reported HBV infections among 
persons aged ≥19 years
STATUS
Source: CDC, National Notifiable Diseases Surveillance System (data run, April 28, 2017)
*Rate per 100,000 U.S. population
The rate of reported acute 
HBV infections among 
persons aged ≥19 years 
increased from 1.16 per 
100,000 U.S. population in 
2014 to 1.38 per 100,000 in 
2015, negating much of the 
progress that had been 
made since 2010. Because of 
this increase, the 2015 target 
of 1.05 cases per 100,000 
U.S. population was not met.
Reduction needed to 
meet 2020 goal: 
A 63.8% reduction from the 2015 reported acute 
HBV infection rate is needed to meet the 2020 
goal of 0.50 cases per 100,000 U.S. population.  
This reduction can best be achieved by 
• Updating CDC recommendations for hepatitis B vaccination to target 
vaccination among emerging at-risk populations.
• Promoting implementation of vaccine recommendations through 
provider education, strategic partnerships, and other measures.
• Building capacity for states to collect and use a core set of surveillance 
data to detect populations at risk and gaps in vaccination coverage. 
• Conducting prevention research to demonstrate how to provide hepatitis 
B vaccination, testing, and treatment as part of a comprehensive set of 
interventions for persons who inject drugs.
• Encouraging unvaccinated individuals to use HHS’s Adult Vaccine Finder 
























Incidence rate* of reported HBV infections among persons 
aged ≥19 years, by sex
In 2015, the HBV incidence 
rate among adult men 
was 1.7 times that of adult 
women. Incidence rates for 
both adult men and women 
fell short of the 2020 goal of 
less than 0.5 acute cases 
per 100,000 U.S. population.
Incidence rate* of reported HBV infections among persons 
aged ≥19 years, by age group
Persons aged 30-59 years 
have the highest rates of 
acute HBV, and rates in 
these groups increased 
during 2014-2015. Those 
aged ≥60 years have the 
lowest incidence rates, 
already below the 2020 goal.
Incidence rate* of reported HBV infections among persons 
aged ≥19 years, by race/ethnicity
Incidence rates of HBV 
infections in adult non-Hispanic 
black persons decreased from 
2010-2014, eliminating previous 
disparities between blacks and 
whites; however, incidence  
rates in both groups increased 
in 2015. Hispanic and Asian/
Pacific Islander adults are the 
only groups with incidence  
rates at or below the 2020 goal.
Source: CDC, National Notifiable Diseases Surveillance System (data run, April 28, 2017)
























B Reduce the rate of HBV-related deaths
Age-adjusted rate* of HBV-related deaths†
STATUS
Source: CDC, National Vital Statistics System7,12
*Rates are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International 






from 0.50 per 
100,000 U.S. 
population in 
2014 to 0.45 
per 100,000 
in 2015, and 
it is already 
below the 
2020 goal 
of 0.48 per 
100,000. 
The 2020 goal will be met by maintaining the current HBV-related death rate.
Further reduction can best be achieved by
• Increasing the proportion of persons 
tested for HBV infection.
• Increasing the proportion of currently 
infected persons who are referred for 
care and receiving appropriate treatment.
• Developing trainings, technical 
assistance, and tools for primary care 
and other health care providers to 
support implementation of HBV testing 
and referral to care.
• Using digital technology and 
telemedicine models to expand access to 
specialty health care providers. 
• Developing innovative/useful clinical 
decision support tools that increase 
implementation of HBV screening, 
testing, and linkage to care.
• Conducting cost-benefit analyses to 
determine how payer policies can 
be revised to expand access to HBV 
services.
• Supporting research and development for 
new and more effective HBV therapies 

























Age-adjusted rate* of HBV-related deaths,† by sex
Men have more than 3 
times higher age-adjusted 
HBV-related death rates 
than women.
Rate of HBV-related deaths per 100,000 population,† by age group‡
Persons aged 55-74 years 
have the highest HBV-
related death rates. The 
HBV-related death rates 
have begun to decrease for 
persons aged 55-64 years in 
the most recent years.  
Age-adjusted rate* of HBV-related deaths,† by race/ethnicity¶
Asian/Pacific Islanders have 
the highest age-adjusted 
HBV-related death rates, 
nearly 3 times higher than 
any other group. 
Source: CDC, National Vital Statistics System7,12
*Rates for sex and race/ethnicity are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International 
Classification of Disease, 10th Revision (ICD-10) codes B16, B17.0, B18.0, and B18.1.
‡1 death in 2015 is not represented due to missing age data.
¶6 deaths in 2010, 7 deaths in 2011, 5 deaths in 2012, 7 deaths in 2013, 16 deaths in 2014, and 16 deaths in 2015 are not represented due to 
missing race/ethnicity data.
26
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C Reduce the rate of reported acute  HCV infections 
Incidence rate* of reported HCV infections
STATUS
Source: CDC, National Notifiable Diseases Surveillance System (data run, April 28, 2017)
*Rate per 100,000 U.S. population
The rate of acute HCV infections 
reported to CDC has increased 
since 2010 to 0.81 cases per 
100,000 U.S. population in 2015, 
well above the 2015 target rate 
of 0.66 per 100,000. Recent 
increases are thought to reflect 
both true increases in incidence 
and, to a lesser extent, 
improved case ascertainment. 
Injection drug use is the most 
common risk reported for 
persons with HCV infection, 
and increases in HCV incidence 
are temporally associated with 
increases in this risk behavior. 
A small proportion of cases can 
be attributed to healthcare-
associated outbreaks of HCV. In 
2014, CDC participated in four 
state-based investigations of 
this type. 
Reduction needed to 
meet 2020 goal: 
A 69.1% reduction from the 2015 reported acute 
HCV infection rate is needed to meet the 2020 
goal of 0.25 cases per 100,000 U.S. population. 
This reduction can best be achieved by 
• Supporting local, state, and federal 
public health surveillance and other data 
collection initiatives to detect where 
HCV transmission is occurring and 
provide evidence to guide strategies 
aimed at reducing hepatitis C incidence.
• Applying advanced molecular, 
computational, and information 
technologies to strengthen the laboratory 
capacity of state and local health 
departments for outbreak investigations.
• Providing HCV-related health services, 
including routine HCV testing of persons 
at risk for HCV infection and appropriate 
care and curative HCV treatment for 
persons living with hepatitis C.
• Supporting implementation of 
comprehensive community-level 
programs for PWID (e.g., access to 
syringe services programs, linkage to 
medication-assisted treatment programs, 
vaccination, testing, and treatment).
• Conducting prevention research to 
improve the effectiveness of HCV 
prevention and decrease HCV incidence.
• Building partnerships to promote 
implementation of prevention strategies 
in settings associated with increased 
























Incidence rate* of reported HCV infections, by sex
Men have 20% higher rates 
of acute HCV infection 
than women; rates are 
increasing in both groups.
Incidence rate* of reported HCV infections, by age group
Young adults have the 
highest rates of acute HCV 
infections, and rates in this 
group are increasing at a 
higher rate than other age 
groups. 
Incidence rate* of reported HCV infection, by race/ethnicity
American Indian/Alaska 
Natives have the highest 
incidence rates of reported 
HCV infections, followed by 
non-Hispanic whites. 
Source: CDC, National Notifiable Diseases Surveillance System (data run, April 28, 2017)
























C Reduce the rate of HCV-related deaths
Age-adjusted rate* of HCV-related deaths†
STATUS
Source: CDC, National Vital Statistics System7,12
*Rates are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International 






2013, but began 
to decline in 
2014. Despite this 
recent decline, 
the observed 2015 
HCV-related death 
rate was above the 
2015 annual target 
of 4.87 deaths 
per 100,000 U.S. 
population. 
Reduction needed 
to meet 2020 goal: 
A 15.1% further reduction from the death rate reported in 
2015 is needed to meet the 2020 goal of 4.17 deaths per 
100,000 U.S. population.  
This reduction can best be achieved by 
• Increasing the proportion of persons 
receiving recommended testing for HCV.
• Increasing the proportion currently 
infected persons who are referred 
for care and receiving appropriate 
treatment.
• Fostering collaborations that increase 
HCV drug affordability, cost savings 
for payers, and access for patients.
• Disseminating tools (e.g., telemedicine 
models) that help healthcare systems 
expand their capacity to identify, link 
to care, and treat persons living with 
hepatitis C.
• Implementing educational campaigns 
to encourage testing and dispel myths 
about who is at increased risk for 
HCV infection.
• Using case surveillance and 
electronic health records to ensure 
HCV infected persons are identified 
























Age-adjusted rate* of HCV-related deaths,† by sex
Men have more than 2.7 
times higher age-adjusted 
HCV-related death rates 
than women.
Rate of HCV-related deaths per 100,000 population,† by age group‡
Persons aged 55-64 years 
have the highest HCV-
related death rates. Death 
rates for persons 65-74 years 
have increased since 2010. 
Age-adjusted rate* of HCV-related deaths,† by race/ethnicity¶
American Indians/Alaska 
Natives have the highest 
death rates of all racial/
ethnic populations, and rates 
for this group increased by 
16% from 2014 to 2015. Death 
rates are also elevated for 
non-Hispanic black and 
Hispanic persons compared 
with other populations. 
Source: CDC, National Vital Statistics System7,12
*Rates for sex and race/ethnicity are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the International Classification of 
Disease, 10th Revision (ICD-10) codes B17.1 and B18.2.
‡2 deaths in 2010, 1 death in 2011, 2 deaths in 2012, 2 deaths in 2013, 5 deaths in 2014, and 1 death in 2015 are not represented due to missing age data.
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Increase the percentage of children aged 19–35 months who 
receive ≥2 doses of hepatitis A vaccine 
GOAL:
By 2020, increase 
the percentage 
of children aged 
19–35 months 
who receive ≥2 
doses of hepatitis 
A vaccine to 85%
INDICATOR:
Percentage of children aged 19–35 months who 
received ≥2 doses of hepatitis A vaccine
Data Source: CDC, National Immunization Survey-Child 
(NIS-Child)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of children aged 19-35 months who 
had received ≥2 doses of hepatitis A vaccine
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Number of children aged 19-35 months
Indicator Notes:10-11,13 The NIS-Child monitors vaccination coverage among children aged 19-35 
months in the 50 states, the District of Columbia, selected local areas, and U.S. territories using a 
random-digit dialing sample of landline and cellular telephone numbers. After identifying a household 
with at least one age-eligible child, a telephone interview is conducted to collect sociodemographic 
characteristics for all age-eligible children and to request permission to contact the child’s vaccination 
providers. If consent is given, a survey is mailed to each provider to request the child’s vaccination 
history, including dates of receipt of vaccine doses. Data are weighted to represent the population of 
children aged 19-35 months, with adjustments for households with multiple telephone lines and mixed 
telephone use (landline and cellular), household nonresponse, and exclusion of households without 
telephone service. Beginning in 2011, surveys include landline and cellular telephone households. 
NIS-Child data for 2010 include children born January 2007 through May 2009; for 2011, children born 
January 2008 through May 2010; for 2012, children born January 2009 through May 2011; for 2013, 
children born January 2010 through May 2012; for 2014, children born January 2011 through May 2013; 
and for 2015, children born January 2012 through May 2014.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators in 
this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s National Viral 
Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional context for data trends. 
The 2020 goal of 85% was set to be consistent with the Healthy People 2020 Objective (IID-7.8) to maintain 
consistency with national programs, regulations, policies, and laws, and because this goal is achievable given 
low hepatitis A vaccination coverage levels compared with other recommended childhood vaccinations. 
Annual targets assume a constant (linear) rate of change from the observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Low response rates, incomplete sampling frames, and potential misclassification 
of vaccination status in the NIS-Child may lead to bias in estimating vaccination coverage. NIS-Child 
estimates of ≥2 hepatitis A doses likely underestimate the proportion of children who ultimately reach 
complete vaccination levels. Children are recommended to receive a dose of hepatitis A vaccine at age 
12–23 months, with a second dose 6–18 months later. Therefore, a child could be on schedule but not 
receive the second dose of hepatitis A vaccine until age 41 months; this second dose would not be 














Reduce the rate of reported HAV infections
GOAL:
By 2020, reduce 
the rate of 
reported HAV 
infections to 0.30 
per 100,000 U.S. 
population
INDICATOR:
Incidence rate of reported HAV infections 
Data Source: CDC, National Notifiable Diseases 
Surveillance System (NNDSS); and CDC/NCHS/US Census 
Bureau, Bridged-race Population Estimates
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of HAV infections reported annually
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Total population in reporting states
Indicator Notes:7 The NNDSS is a nationwide collaboration that enables all levels of public 
health to share notifiable-disease-related health information. In some jurisdictions, viral hepatitis is a 
reportable disease: health care providers, hospitals, and laboratories are mandated to report cases to 
the state health department. In other jurisdictions, viral hepatitis is a notifiable disease, rendering such 
case reporting voluntary. Each state has its own laws and regulations defining whether viral hepatitis is 
reportable or notifiable. CDC in turn receives voluntary viral hepatitis case notification from each state 
or reporting jurisdiction. Surveillance for viral hepatitis through NNDSS is based on case definitions 
developed and approved by the Council of State and Territorial Epidemiologists (CSTE) and CDC. 
Reported cases of acute viral hepatitis A are required to meet specific clinical and laboratory criteria. 
Only these confirmed cases of acute viral hepatitis are presented in this report. Case rates per 100,000 
U.S. population are calculated based on the resident population of the United States for the data years 
involved. For census years (e.g., 2010), population counts enumerated as of April 1 are used. For all 
other years, population estimates as of July 1 are used.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: 2014 was established as the baseline year for this indicator to maintain uniformity 
across all indicators in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-
2020 and HHS’s National Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to 
provide additional context for data trends. The 2020 goal of 0.30 per 100,000 U.S. population was set to 
be consistent with the Healthy People 2020 Objective (IID-23), and CDC’s Viral Hepatitis Strategic Plan, 
2016-2020. Annual targets assume a constant (linear) rate of change from the observed baseline (2014) 
to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Viral hepatitis is largely underreported in the NNDDS: based on a simple probabilistic 
model for estimating the fraction of patients who would have been symptomatic, sought health care 
tests, and reported to health officials in 2015, actual HAV cases are estimated to be 1.96 times the 
number reported to CDC.14 Additionally, rates may vary over time based on changes in public and 
















Increase the percentage of infants who receive hepatitis B vaccine 
within 3 days of birth 
GOAL:
By 2020, increase 
the percentage 
of infants who 
receive hepatitis 
B vaccine within 
3 days of birth to 
85%
INDICATOR:
Percentage of children aged 19-35 months who 
received hepatitis B vaccine within 3 days of birth
Data Source: CDC, National Immunization Survey-Child 
(NIS-Child)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of children aged 19-35 months who 
received hepatitis B vaccine within 3 days of birth
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Number of children aged 19-35 months 
Indicator Notes:10-11,13 The NIS-Child monitors vaccination coverage among children aged 19-35 
months in the 50 states, the District of Columbia, selected local areas, and U.S. territories using a 
random-digit dialing sample of landline and cellular telephone numbers. After identifying a household 
with at least one age-eligible child, a telephone interview is conducted to collect sociodemographic 
characteristics for all age-eligible children and to request permission to contact the child’s vaccination 
providers. If consent is given, a survey is mailed to each provider to request the child’s vaccination 
history, including dates of receipt of vaccine doses. Data are weighted to represent the population of 
children aged 19-35 months, with adjustments for households with multiple telephone lines and mixed 
telephone use (landline and cellular), household nonresponse, and exclusion of households without 
telephone service. Beginning in 2011, surveys include landline and cellular telephone households.  
NIS-Child data for 2010 include children born January 2007 through May 2009; for 2011, children born 
January 2008 through May 2010; for 2012, children born January 2009 through May 2011; for 2013, 
children born January 2010 through May 2012; for 2014, children born January 2011 through May 2013; 
and for 2015, children born January 2012 through May 2014.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators 
in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s 
National Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional 
context for data trends. The 2020 goal of 85% was set to be consistent with the Healthy People 2020 
Objective (IID-7.9) to maintain consistency with national programs, regulations, policies, and laws and 
based on modeling of NIS data from 2003-2008, which showed an average increase of 2.46% per 
year, making 85% coverage an achievable 2020 goal. The 85% Healthy People 2020 goal was also 
subsequently adopted in both CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s National Viral 
Hepatitis Action Plan, 2017-2020. Annual targets assume a constant (linear) rate of change from the 
observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Low response rates, incomplete sampling frames, and potential misclassification of 















Reduce the rate of reported acute HBV infections among persons 
aged ≥19 years
GOAL:
By 2020, reduce 




aged ≥19 years to 
0.50 per 100,000 
U.S. population
INDICATOR:
Incidence rate of reported HBV infections among 
persons aged ≥19 years 
Data Source: CDC, National Notifiable Diseases 
Surveillance System (NNDSS); and CDC/NCHS/U.S. Census 
Bureau, Bridged-race Population Estimates
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of acute HBV infections reported 
among persons aged ≥19 years annually
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Total population of persons aged ≥19 years in 
reporting states
Indicator Notes: The NNDSS is a nationwide collaboration that enables all levels of public health 
to share notifiable-disease-related health information. In some jurisdictions, viral hepatitis is a reportable 
disease: health care providers, hospitals, and laboratories are mandated to report cases to the state health 
department. In other jurisdictions, viral hepatitis is a notifiable disease, making case reporting voluntary. Each 
state has its own laws and regulations defining whether viral hepatitis is reportable or notifiable. CDC in turn 
receives voluntary viral hepatitis case notification from each state or reporting jurisdiction. Surveillance for 
viral hepatitis through the NNDSS is based on case definitions developed and approved by CSTE and CDC. 
Reported cases of acute viral hepatitis B are required to meet specific clinical and laboratory criteria. Only 
these confirmed cases are presented in this report. Case rates per 100,000 U.S. population are calculated 
based on the resident population of the United States for the data years involved. For census years (e.g., 
2010), population counts enumerated as of April 1 are used. For all other years, population estimates as of 
July 1 are used. 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators 
in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s National 
Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional context for data 
trends. The 2020 goal of 0.50 per 100,000 U.S. population aged ≥19 years was set to be consistent with the 
Healthy People 2020 Objective (IID-25.1) and CDC’s Viral Hepatitis Strategic Plan, 2016-2020. Annual targets 
assume a constant (linear) rate of change from the observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Viral hepatitis is largely underreported in the NNDDS: based on a simple probabilistic 
model for estimating the fraction of patients who would have been symptomatic, sought health care tests, 
and reported to health officials in 2015, the actual number of acute HBV cases for all age groups combined 
is estimated to be 6.48 times the number reported to CDC.14 Additionally, rates may vary over time based on 
changes in public and provider awareness, changes in laboratory and diagnostic techniques, and changes in 















Reduce the rate of HBV-related deaths
GOAL:
By 2020, reduce 
the rate of  
HBV-related 
deaths to  




Age-adjusted rate of HBV-related deaths
Data Source: CDC, National Vital Statistics System (NVSS)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of death records with a report of 
hepatitis B listed as the underlying or one of multiple causes  
of death
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Total U.S. Census population
Indicator Notes:7,12,15 Death certificates are completed for all deaths registered in the United 
States. Information for death certificates is provided by funeral directors, attending physicians, medical 
examiners, and coroners, and certificates are filed in vital statistics offices within each state and the 
District of Columbia. Through the NVSS, information from death certificates is compiled by CDC to 
produce national multiple-cause-of-death data; causes of death are coded in accordance with the 
International Classification of Diseases, Tenth Revision.16 National multiple-cause mortality data from 
NVSS were obtained and analyzed, and those death records with a report of hepatitis B (ICD-10: B16, 
B17.0, B18.0, or B18.1) listed as the underlying or one of the multiple (e.g., contributing) causes of death 
in the record were enumerated. Rates were calculated as the number of deaths related to hepatitis 
B divided by the total U.S. Census population. Rates for race/ethnicity, sex, and overall total were 
standardized to the age distribution of the U.S. standard population in 2000. 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators 
in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s 
National Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional 
context for data trends. A goal of reducing the number of deaths from viral hepatitis B from 1,843 in 
2014 to 1,754 in 2020 was set in CDC’s Viral Hepatitis Strategic Plan, 2016-2020, and a similar goal was 
defined in HHS’s National Viral Hepatitis Action Plan, 2017-2020. However, death counts are susceptible 
to changes in the distribution of the underlying population, potentially confounding trends over time. 
For purposes of this report, a proportional reduction goal was applied to the 2014 rate (0.50 deaths per 
100,000 U.S. population) instead of the count. Annual targets assume a constant (linear) rate of change 
from the observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Mortality data must be interpreted with caution due to the potential for 
misclassification of ICD-10 codes on the death record, underrepresentation of certain racial/ethnic 
















Reduce the rate of reported acute HCV infections
GOAL:
By 2020, reduce 
the rate of 
reported acute 
HCV infections to 
0.25 per 100,000 
U.S. population
INDICATOR:
Incidence rate of reported HCV infections 
Data Source: CDC, National Notifiable Diseases 
Surveillance System (NNDSS); and CDC/NCHS/U.S. Census 
Bureau, Bridged-race Population Estimates
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of acute HCV infections reported annually
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Total population in reporting states
Indicator Notes:7 The NNDSS is a nationwide collaboration that enables all levels of public health 
to share notifiable-disease-related health information. In some jurisdictions, viral hepatitis is a reportable 
disease: health care providers, hospitals, and laboratories report cases to the state health department. 
In other jurisdictions, viral hepatitis is a notifiable disease, rendering such reporting voluntary. Each state 
has its own laws and regulations defining whether viral hepatitis is reportable or notifiable. CDC in turn 
receives voluntary viral hepatitis case notification from each state or reporting jurisdiction. Surveillance 
for viral hepatitis through the NNDSS is based on case definitions developed and approved by CSTE 
and CDC. Reported cases of acute viral hepatitis C are required to meet specific clinical and laboratory 
criteria. Only these confirmed cases are presented in this report. Case rates per 100,000 U.S. population 
are calculated based on the resident population of the United States for the data years involved. For 
census years (e.g., 2010), population counts enumerated as of April 1 are used. For all other years, 
population estimates as of July 1 are used. 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators 
in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s 
National Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional 
context for data trends. The 2020 goal of 0.25 per 100,000 U.S. population was set to be consistent with 
the Healthy People 2020 Objective (IID-26) and CDC’s Viral Hepatitis Strategic Plan, 2016-2020. Annual 
targets assume a constant (linear) rate of change from the observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Viral hepatitis is largely underreported in the NNDDS: based on a simple probabilistic 
model for estimating the fraction of patients who would have been symptomatic, sought health care 
tests, and reported to health officials in 2015, the actual number of acute HCV cases is estimated to 
be 13.9 times the number reported to CDC.14 Additionally, rates may vary over time based on changes 
in public and provider awareness, changes in laboratory and diagnostic techniques, and changes in the 















Reduce the rate of HCV-related deaths
GOAL:
By 2020, reduce 
the rate of  
HCV-related 
deaths to 4.17  
per 100,000  
U.S. population
INDICATOR:
Age-adjusted rate of HCV-related deaths
Data Source: CDC, National Vital Statistics System (NVSS)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Numerator: Number of death records with a report of hepatitis 
C listed as the underlying or one of multiple causes of death
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Denominator: Total U.S. Census population
Indicator Notes:7,12,15 Death certificates are completed for all deaths registered in the United 
States. Information for death certificates is provided by funeral directors, attending physicians, medical 
examiners, and coroners, and certificates are filed in vital statistics offices within each state and the 
District of Columbia. Through the NVSS, information from death certificates is compiled by CDC to 
produce national multiple-cause-of-death data; causes of death are coded in accordance with the 
International Classification of Diseases, Tenth Revision.16 National multiple-cause mortality data from 
NVSS were obtained and analyzed, and those death records with a report of hepatitis C (ICD-10: B16, 
B17.0, B18.0, or B18.1) listed as the underlying or one of the multiple (e.g., contributing) causes of death 
in the record were enumerated. Rates were calculated as the number of deaths related to hepatitis 
C divided by the total U.S. Census population. Rates for race/ethnicity, sex, and overall total were 
standardized to the age distribution of the U.S. standard population in 2000.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Goal Setting: Data from 2014 were chosen as a baseline to maintain uniformity across all indicators 
in this report and to be consistent with CDC’s Viral Hepatitis Strategic Plan, 2016-2020 and HHS’s 
National Viral Hepatitis Action Plan, 2017-2020. Data prior to 2014 are presented to provide additional 
context for data trends. A goal of reducing the number of deaths from viral hepatitis C from 19,659 in 
2014 to 16,370 in 2020 was set in CDC’s Viral Hepatitis Strategic Plan, 2016-2020, and a similar goal was 
defined in HHS’s National Viral Hepatitis Action Plan, 2017-2020. However, because death counts are 
susceptible to changes in the distribution of the underlying population potentially confounding trends 
over time, for purposes of this report, a proportional reduction goal was applied to the 2014 rate (5.01 
deaths per 100,000 U.S. population) instead of the count. Annual targets assume a constant (linear) rate 
of change from the observed baseline (2014) to the 2020 goal.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Limitations: Mortality data must be interpreted with caution due to the potential for misclassification 
of ICD-10 codes on the death record, underrepresentation of certain racial/ethnic populations in U.S. 
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